BCRX BioCryst Pharmaceuticals Inc.

7.92
+0.23  (+3%)
Previous Close 7.69
Open 7.71
Price To Book 17.6
Market Cap 873340420
Shares 110,270,255
Volume 1,133,049
Short Ratio
Av. Daily Volume 819,173

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved September 21, 2017.
RAPIVAB (peramivir injection)
Acute uncomplicated influenza to pediatric patients
Phase 3 trial to commence summer 2019.
BCX7353
Angioedema attacks in patients with hereditary angioedema (HAE)
Phase 3 data due 2Q 2019.
BCX7353 - APeX-2
Reduce or eliminate attacks in HAE patients
Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Approved Dec 22 2014
RAPIVAB (peramivir)
INFLUENZA ACUTE
Dosing of first patient in long-term safety trial announced February 28, 2018.
BCX7353 - APeX-S
Hereditary angioedema (HAE)
Phase 1 trial initiation announced January 2, 2019.
Galidesivir
Healthy volunteers
Phase 1 trial to be initiated 2Q 2019 with data due 4Q 2019.
BCX9930
Healthy subjects

Latest News

  1. Implied Volatility Surging for BioCryst Pharmaceuticals (BCRX) Stock Options
  2. BioCryst to Present at Upcoming Investor Conferences
  3. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): What Can We Expect From This High Growth Stock?
  4. Edited Transcript of BCRX earnings conference call or presentation 4-Mar-19 1:30pm GMT
  5. Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics — Future Expectations, Projections Moving into 2019
  6. Biocryst Pharmaceuticals Inc (BCRX) Q4 2018 Earnings Conference Call Transcript
  7. BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results
  8. BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development
  9. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
  10. BioCryst to Present at Barclays Global Healthcare Conference
  11. Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for
  12. BioCryst Reports ZENITH-1 Results With Oral BCX7353 Which Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response for Treatment of Acute HAE Attacks
  13. BioCryst to Report Fourth Quarter and Full Year 2018 Financial Results on March 4
  14. The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
  15. Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
  16. Detailed Research: Economic Perspectives on Callon Petroleum, Summit Materials, Echo Global Logistics, BioCryst Pharmaceuticals, NEXEO SOLUTIONS, and NL Industries — What Drives Growth in Today's Competitive Landscape
  17. How CEO Stonehouse is building up BioCryst's war chest to finance trials, drug launch
  18. BioCryst Strengthens Cash Position With Flexible $100 Million Debt Facility
  19. BioCryst to Present ZENITH-1 Results at American Academy of Allergy, Asthma & Immunology Annual Meeting
  20. BioCryst Appoints Steve Aselage to Board of Directors